Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker ONCY · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Muta… NCT07446322 · Ras-mutated Metastatic Colorectal Cancer, mCRC Bevacizumab, FOLFIRI | ONCY Oncolytics Biotech | Phase 2 | Recruiting | 60 | Aug 30, 2027 | Registry ↗ |
| May 19, 2026 | A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pe… NCT07280377 · Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus… Pelareorep, Atezolizumab | ONCY Oncolytics Biotech | Phase 1/2 | Active, not recruiting | 122 | Jul 30, 2027 | Registry ↗ |
| Jan 16, 2025 | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast… NCT04215146 · Breast Cancer Metastatic Paclitaxel, Pelareorep | ONCY Oncolytics Biotech | Phase 2 | Active, not recruiting | 48 | Aug 1, 2022 | Registry ↗ |
| Aug 15, 2022 | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer NCT04102618 · Breast Cancer Pelareorep, Letrozole | ONCY Oncolytics Biotech | Early phase 1 | Terminated | 26 | Apr 20, 2022 | Registry ↗ |
| Dec 19, 2018 | Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS… NCT01274624 · KRAS Mutant Metastatic Colorectal Cancer REOLYSIN®, Irinotecan | ONCY Oncolytics Biotech | Phase 1 | Completed | 36 | Feb 2018 | Registry ↗ |
| Sep 13, 2018 | Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenoca… NCT02620423 · Pancreatic Adenocarcinoma REOLYSIN®, Chemotherapy | ONCY Oncolytics Biotech | Phase 1 | Completed | 11 | Mar 2018 | Registry ↗ |
| Mar 7, 2017 | Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therap… NCT02723838 · Muscle-invasive Transitional Cell Carcinoma of the Bladder REOLYSIN®, Gemcitabine | ONCY Oncolytics Biotech | Phase 1 | Withdrawn | 0 | Sep 30, 2017 | Registry ↗ |
| Mar 31, 2016 | A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell… NCT00998192 · Metastatic or Recurrent Squamous Cell Carcinoma of the Lung REOLYSIN, Paclitaxel | ONCY Oncolytics Biotech | Phase 2 | Completed | 32 | Sep 2013 | Registry ↗ |
| Dec 2, 2015 | Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung C… NCT00861627 · Carcinoma, Non-small Cell Lung REOLYSIN®, Carboplatin | ONCY Oncolytics Biotech | Phase 2 | Completed | 37 | Sep 2015 | Registry ↗ |
| Apr 10, 2015 | A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarc… NCT00998322 · Metastatic Pancreatic Adenocarcinoma REOLYSIN, Gemcitabine | ONCY Oncolytics Biotech | Phase 2 | Completed | 34 | Dec 2013 | Registry ↗ |
| Apr 10, 2015 | Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melan… NCT00984464 · Metastatic Melanoma REOLYSIN, Carboplatin | ONCY Oncolytics Biotech | Phase 2 | Completed | 14 | Feb 2014 | Registry ↗ |
11 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:21 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances